V-set and transmembrane domain-containing protein（VSTM）家族是跨膜免疫球蛋白（Ig）超家族。其在结构上与B7-like免疫调节蛋白相似，并且拥有IgV-like和/或IgC-like胞外域。VSTM家族由8种蛋白组成：VSTM1v1、VSTM1v2、VSTM2a、VSTM2b、VSTM2L、VSTM3、VSTM4和VSTM5。据文献报道，VSTM家族成员与免疫细胞、脂肪细胞和神经元细胞的内在功能调节相关。目前大部分关于VSTM家族的研究都集中于其免疫功能上，例如，已证明VSTM1和VSTM4在巨噬细胞的激活中发挥积极或消极的作用。VSTM3（TIGIT、VSIG9）作为共抑制受体，可抑制T细胞和NK细胞的细胞因子产生。而与其他的免疫调节VSTM家族成员不同，VSTM2与脂肪生成过程中的脂肪前体调节有关。
参考文献：VSTM5 is a novel immune checkpoint that promotes oral tolerance of cell-mediated and antibody responses: O.E. Oludada, et al.; BBRC 635, 283 (2022)
Glucagon-like peptide 1 (1-37), human TFA;(Synonyms: HuGLP-1 TFA) 纯度: 97.18%
Glucagon-like peptide 1 (1-37), human (TFA) 是有效的 GLP-1 受体激动剂。
Glucagon-like peptide 1 (1-37), human TFA Chemical Structure
规格
价格
是否有货
数量
500 μg
￥2970
In-stock
1 mg
￥4840
In-stock
5 mg
;
询价
;
10 mg
;
询价
;
* Please select Quantity before adding items.
Glucagon-like peptide 1 (1-37), human TFA 相关产品
bull;相关化合物库:
Bioactive Compound Library Plus
Peptide Library
生物活性
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.
IC50 Target
GLP-1 receptor[1].
体外研究 (In Vitro)
Glucagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proglucagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4h exposure to mouse serum. GLP-1(1-37) is confirmed to be a highly potent agonist of the GLP-1 receptor (GLP-1R) by measuring the expression of the luciferase reporter gene expression in transiently transfected human embryonic kidney (HEK293) cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)
GLP-1(1–37) decreases glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Room temperature in continental US; may vary elsewhere.
储存方式
Sealed storage, away from moisture and light
Powder
-80deg;C
2 years
-20deg;C
1 year
*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)
溶解性数据
In Vitro:;
H2O : 25 mg/mL (5.84 mM; Need ultrasonic)
配制储备液
浓度溶剂体积质量
1 mg
5 mg
10 mg
1 mM
0.2335 mL
1.1673 mL
2.3345 mL
5 mM
0.0467 mL
0.2335 mL
0.4669 mL
10 mM
—
—
—
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献
[1]. Zhao L, et al. Glucagon-like peptide-1(1-37) can enhance blood glucose homeostasis in mice. Regul Pept. 2012 Oct 10;178(1-3):1-5.
Cell Assay [1]
HEK293 cells (5×104) are seeded in a 96-well plate and transiently cotransfected with the GLP-1R plasmid and the CRE-luciferase reporter plasmid. After a 48 h transfection, different concentrations of GLP-1(1–37) or GLP-1(7–37) (TFA) are added, and the cells are incubated for 5 h. The cells are harvested for a luciferase assay using a luciferase assay[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration [1]
Mice[1]
The normal KM mice are fasted for 16 h before the administration (i.p.) of GLP-1 and glucose. GLP-1(1-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is given in combination with glucose (4 g/kg). GLP-1(7-37) (25 nmol/kg) with or without exendin(9-39) (250 nmol/kg) is also administrated in combination with glucose (4 g/kg). The control group is treated with saline (NaCl, 9 g/L) and glucose (4 g/kg). The IPGTT is carried out at 0, 15, 30 and 60 min after glucose and protein administration, and the blood glucose levels are measured as described above[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献
[1]. Zhao L, et al. Glucagon-like peptide-1(1-37) can enhance blood glucose homeostasis in mice. Regul Pept. 2012 Oct 10;178(1-3):1-5.
